Business Context and Reporting Period
This Form 8-K was filed by AquaBounty Technologies, Inc. on April 26, 2018, reporting events occurring on April 26 and April 27, 2018. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a Current Report regarding a regulatory event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event is the U.S. Food and Drug Administration (FDA) approval on April 26, 2018, of a supplemental New Animal Drug Application (Supplemental NADA). This approval permits the company to raise its AquAdvantage Salmon product at a land-based contained facility near Albany, Indiana. This facility was previously approved for production in 2015.
Outlook, Risks, and Contingencies
Despite the FDA approval for the Indiana facility, the company faces a significant regulatory contingency. The filing states that the company is currently prohibited from importing the eggs necessary to produce genetically engineered salmon at this facility due to a requirement in the FDA's current appropriations law. This restriction prevents immediate commercial production at the newly approved site.
Investor Verification Checklist
- Verify the specific provisions in the FDA's current appropriations law that prohibit the import of eggs for the Indiana facility.
- Confirm the timeline for potential legislative changes required to lift the import prohibition.
- Review the full text of the press release (Exhibit 99.1) for additional operational details regarding the Albany, Indiana facility.
- Assess the impact of this regulatory hurdle on the company's projected revenue timeline for AquAdvantage Salmon.